How does Super Vilitra affect the production of cyclic guanosine monophosphate (cGMP)?
Super Vilitra is a medication that combines two active ingredients, Vardenafil (a phosphodiesterase type 5 or PDE-5 inhibitor) and Dapoxetine (a selective serotonin reuptake inhibitor or SSRI). Each of these components has a specific mechanism of action.
Vardenafil (PDE-5 Inhibitor): Vardenafil works primarily by inhibiting the enzyme phosphodiesterase type 5 (PDE-5). PDE-5 is responsible for breaking down cyclic guanosine monophosphate (cGMP), a molecule that plays a crucial role in regulating blood flow in the penis. When a man is sexually aroused, the release of nitric oxide (NO) leads to increased levels of cGMP in the smooth muscle cells of the penis. This causes relaxation of the smooth muscles and an increase in blood flow, leading to an erection. By inhibiting PDE-5, Vardenafil prolongs the presence of cGMP in the smooth muscle cells, helping to maintain an erection and improve erectile function.
Dapoxetine (SSRI): Dapoxetine is used in Super Vilitra to treat premature ejaculation (PE). It is a selective serotonin reuptake inhibitor (SSRI), which means it increases the levels of serotonin in the brain. Serotonin is a neurotransmitter that plays a role in controlling ejaculation. By increasing serotonin levels, Dapoxetine can help delay ejaculation and improve control over ejaculation during sexual activity.
It’s important to note that Super Vilitra 80 mg is a combination medication designed to address both erectile dysfunction (ED) and premature ejaculation in men. It should only be used under the guidance and prescription of a qualified healthcare provider. The interaction of the two active ingredients in Super Vilitra allows it to address both physical and psychological factors that may contribute to sexual performance issues in men. However, it may also have specific contraindications and potential side effects, so it should be used according to a healthcare provider’s instructions.